|Last Price||Today's Change||52-Week Range||Trading Volume|
|51.18||-0.17 (-0.33%)||45.70 - 57.49||6.1 million|
Market data as of 4:00PM 09/30/14. Quotes are delayed by at least 15 min.
Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
09/29/2014 3:00 AM ET